Skip to main content

Table 5 Cause of death

From: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

 

Overall (n = 564)

de novo (n = 485)

sAML (n = 79)

Original disease

201 (37.2%)

169 (36.3%)

32 (42.1%)

Infection

162 (29.9%)

142 (30.5%)

20 (26.3%)

GVHD

75 (13.9%)

68 (14.6%)

7 (9.2%)

Non HSCT related

34 (6.3%)

26 (5.6%)

8 (10.5%)

Other transp related

17 (3.1%)

17 (3.7%)

0 (0%)

MOF

14 (2.6%)

11 (2.4%)

3 (3.9%)

VOD

10 (1.8%)

10 (2.2%)

0 (0%)

Cardiac toxicity

7 (1.3%)

6 (1.3%)

1 (1.3%)

Other second malignancy

6 (1.1%)

5 (1.1%)

1 (1.3%)

Haemorhage

6 (1.1%)

4 (0.9%)

2 (2.6%)

Failure/Rejection

4 (0.7%)

3 (0.6%)

1 (1.3%)

CNS toxicity

4 (0.7%)

3 (0.6%)

1 (1.3%)

IP

1 (0.2%)

1 (0.2%)

0 (0%)

Missing

23

20

3

  1. sAML secondary acute myeloid leukemia, GVHD graft-versus-host disease, HSCT hematopoietic stem cell transplantation, MOF multi organ failure, VOD veno-occlusive disease of the liver, CNS central nervous system, IP interstitial pneumonitis